FierceBiotech reports on REVOLUTION Medicines’ recently announced $100M Series C financing and how that funding will help advance the company’s pipeline, which includes programs addressing elusive targets within the RAS pathway such as KRASG12C(GTP) and other specific tumorigenic mutants of RAS.
Revolution Medicines raised $100 million in series C financing to advance a stable of drugs aiming at what it calls “frontier targets” in cancer. These include a program targeting KRAS mutations, which were previously considered undruggable.
FierceBiotech